Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.

Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.

The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium. More specifically, the invention relates to an Enterococcus faecalis and/or Enterococcus faecium antigen which comprises at least one unit having the following general formula:

##STR00001##

The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium. More specifically, the invention relates to an Enterococcus faecalis and/or Enterococcus faecium antigen which comprises at least one unit having the following general formula:

##STR00001##

The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

The invention relates to a citrate-functionalized polyglucoside derivatives, and crosslinked variants thereof, that are made by the reaction of an epichlorohydrin/citric acid ester with an alkyl polyglycoside. These functionalized alkyl polyglucosides are viscosity builders and anti-irritants in personal care cleansing products.

The invention relates to a citrate-functionalized polyglucoside derivatives, and crosslinked variants thereof, that are made by the reaction of an epichlorohydrin/citric acid ester with an alkyl polyglycoside. These functionalized alkyl polyglucosides are viscosity builders and anti-irritants in personal care cleansing products.

A compound of formula I: ##STR00001## or a salt thereof, wherein: R.sup.1 is —OC(H)(X)(CH.sub.2).sub.nC(═O)OH; R.sup.2 is —OH, —N.sub.3, or —N(H)C(═O)CH.sub.3; or R.sup.1 and R.sup.2 together with the carbon atoms to which they are attached form ##STR00002## R.sup.3 is —H, —CH.sub.3, —CH.sub.2C(═O)OH, or —CH.sub.2OH; X is —H, —CH.sub.3, —CH.sub.2OH, or CH.sub.2C(═O)OH; and n is 0 or 1.

A compound of formula I: ##STR00001## or a salt thereof, wherein: R.sup.1 is —OC(H)(X)(CH.sub.2).sub.nC(═O)OH; R.sup.2 is —OH, —N.sub.3, or —N(H)C(═O)CH.sub.3; or R.sup.1 and R.sup.2 together with the carbon atoms to which they are attached form ##STR00002## R.sup.3 is —H, —CH.sub.3, —CH.sub.2C(═O)OH, or —CH.sub.2OH; X is —H, —CH.sub.3, —CH.sub.2OH, or CH.sub.2C(═O)OH; and n is 0 or 1.